Abstract:

A novel coronavirus pneumonia outbroke in Wuhan at the end of 2019. As an acute respiratory infectious disease, it has been included in class B infectious diseases under the infectious disease prevention act of the People's Republic of China and is managed according to class A infectious diseases. Based on the "Novel coronavirus pneumonia diagnosis and treatment formula", the detection of viral nucleic acid in respiratory tract specimen by RT-PCR is one of the confirmed plans of this disease. It is to be noted that a standardized and efficient novel coronavirus nucleic acid detection process is necessary to ensure the safety and reliability of laboratory personnel and to meet the requirements of epidemic prevention and control. KindMed Diagnostics undertakes large-scale testing tasks of 2019-nCOV and constantly optimizes the process under the advice of experts and colleagues. This paper presents here the relevant practical experience.

Key words: Novel coronavirus, Polymerase chain reaction, Protection